ASCENDIS PHARMA A/S's ticker is ASND and the CUSIP is 04351P101. A total of 170 filers reported holding ASCENDIS PHARMA A/S in Q3 2021. The put-call ratio across all filers is 1.45 and the average weighting 0.5%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q1 2023 | $4,824,900 | -12.3% | 45,000 | -0.1% | 0.01% | -14.3% |
| Q4 2022 | $5,503,788 | +5043.7% | 45,065 | +6636.2% | 0.01% | – |
| Q3 2021 | $107,000 | -99.4% | 669 | -99.5% | 0.00% | -100.0% |
| Q2 2021 | $17,760,000 | -19.8% | 134,994 | -21.5% | 0.02% | -24.0% |
| Q1 2021 | $22,151,000 | -18.8% | 171,883 | +5.1% | 0.02% | -26.5% |
| Q4 2020 | $27,273,000 | +86.2% | 163,524 | +72.3% | 0.03% | +88.9% |
| Q3 2020 | $14,647,000 | +4.5% | 94,917 | +0.1% | 0.02% | -5.3% |
| Q2 2020 | $14,020,000 | -35.2% | 94,793 | -50.6% | 0.02% | -47.2% |
| Q1 2020 | $21,645,000 | -8.1% | 191,964 | +13.2% | 0.04% | +9.1% |
| Q4 2019 | $23,556,000 | +32.7% | 169,636 | -8.1% | 0.03% | +22.2% |
| Q3 2019 | $17,747,000 | -28.0% | 184,603 | -13.8% | 0.03% | -27.0% |
| Q2 2019 | $24,663,000 | -15.7% | 214,178 | -13.9% | 0.04% | -19.6% |
| Q1 2019 | $29,271,000 | +268.5% | 248,699 | +96.2% | 0.05% | +228.6% |
| Q4 2018 | $7,943,000 | -0.9% | 126,787 | +12.1% | 0.01% | +16.7% |
| Q3 2018 | $8,016,000 | +247.8% | 113,118 | +226.5% | 0.01% | +300.0% |
| Q2 2018 | $2,305,000 | – | 34,644 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Vivo Capital, LLC | 1,797,745 | $265,886,000 | 19.06% |
| RA Capital Management | 4,914,955 | $726,922,000 | 14.16% |
| Sofinnova Investments, Inc. | 1,109,874 | $164,150,000 | 10.35% |
| Eventide Asset Management | 1,709,848 | $252,887,000 | 5.50% |
| Asymmetry Capital Management, L.P. | 47,599 | $7,040,000 | 5.39% |
| BERYLSON CAPITAL PARTNERS, LLC | 58,200 | $8,608,000 | 5.30% |
| Avoro Capital Advisors LLC | 1,750,000 | $258,825,000 | 5.12% |
| Eversept Partners, LP | 220,344 | $32,588,878 | 4.47% |
| Spyglass Capital Management LLC | 452,104 | $66,866,000 | 4.14% |
| Orbimed Advisors | 1,562,986 | $231,166,000 | 3.25% |